|
|
The 1st International Congress on
Controversies in Longevity, Health and Aging (CoLONGY)
Barcelona, Spain, June 24-27, 2010 |
|
| |
| Scientific Program |
 |
|
|
Registration: 16:00
Welcome Reception: 19:00
| 09:00-10:00 |
Plenary Session |
|
Longevity determinded by aging or by age associated disease |
| Capsule: |
The older persons' population has increased and is the highest consumer of medical services. Is this determined by the biological process of aging or by the burden of age-related health problems, i.e. Alzheimer's, cardiac disease or pulmonary disease? |
| Chairpersons: |
Y. Berner, Israel; B. Vellas, France |
|
|
| 09:00-09:15 |
Opening remarks: B. Vellas, France & E. Topinkova, Czech Republic |
|
|
| 09:15-10:00 |
Debate: Is aging just a collection of diseases or an intrinsic biological process? |
|
Burden of disease in the older persons in Europe: J.B. Baeyens, Belgium |
|
Aging is a biological process with clinical implications: D. Ingram, USA |
|
|
| 10:00-10:30 |
Is it possible to repair molecular and cellular damage of aging and to postpone age-related ill health?
A. de Grey, UK |
|
|
|
10:30-11:00 |
Coffee Break |
|
|
| 11:00-12:00 |
Plenary Session |
|
Treatment of dementia: When to start? |
| Capsule: |
Alzheimer's disease is a common clinical phenomenon. With certian and imaging exams, we can treat it in its early stages. Innovations in therapy, mainly in slowing the procession rate of the disease, are growing. There is a question of starting this medication and innovations in therapeutic trial in healthy subjects or starting once the subjects begin to lose their cognitive abilities |
| Chairpersons: |
T. Salva, Spain; B. Vellas, France |
|
|
| 11:00-11:45 |
Debate: Do we need to propose a therapeutic trial to Alzheimer patients with new innovative drugs? |
|
Yes: B. Vellas, France |
|
No: S. Andrieu, France |
|
|
| 11:45-12:00 |
Genetic tests for Alzheimer's disease in healthy subjects: J. Oliveira, Brazil |
|
|
| 12:00-13:00 |
Plenary Session |
|
Aging and oxidation |
| Capsule: |
Over the last 50 years oxidative stress is one of the leading theories for the development of age associated diseases and of the aging process itself |
| Chairpersons: |
C. Franceschi, Italy; J. Joseph, USA |
|
|
| 12:00-12:15 |
Longevity, inflammation and aging: C. Franceschi, Italy |
|
|
| 12:15-13:00 |
Debate: Oxidation and anti-oxidation in the aging process |
|
Oxidation is a major reason for disease and the aging process. Can reactive oxygen species (ROS) compete or cooperate with prooxidative/antioxidative genes in aging?
I. Afanas'ev, Portugal |
|
What are the effects of botanical compounds and direct antioxidants on oxidative stress levels and aging processes?
S. Anton, USA |
|
|
| 13:00-14:00 |
Lunch Break |
|
|
| 14:00-16:00 |
Parallel Session |
14:00-16:00 |
Parallel Session |
|
Limits of treatment for high blood pressure in older persons |
|
Surgery in older persons
|
|
Capsule: |
Vascular disease & high blood pressure are some of the main reasons for disease and disability in older persons. There is prolonged experience of decreasing vascular mobidity with the treatment of high blood pressure. Recent guidelines are very strict and raise the
quesiton of whether we have to follow them with the physiolgoical changes and other morbidity in older persons |
Capsule: |
A great part of elective and emergency surgery - in general surgery, orthopedic surgery, chest surgery, ear nose and throat (ENT) and the other surgical specialities - are performed on older person patients. Their physiological condtion d eserves some special attitudes. During recent years more attention is given to surgery and especially to anesthesia and pre and post operative care of the older person patient |
| Chairperson: |
Y. Berner, Israel |
Chairperson: |
G. Silvay, USA |
|
|
|
|
|
14:00-14:45 |
Debate: Vascular and blood pressure age-related changes. Determinants, consequences and treatment |
14:00-14:45 |
Debate: Do pre-operative interventions reduce postoperative morbidity/mortality? |
|
Pro, Systolic blood pressure 110mmHg at any rate:
F. Mattace-Raso, The Netherlands |
|
The value of pre-operative beta blocksers in therapy:
G. Gambassi, Italy |
|
Con, Older person systolic blood presure over 130mmHg:
D. Dicker, Israel
|
|
How do you prepare older person patients for a surgery?
G. Silvay, USA
|
| 14:45-16:00 |
Parellel Session |
14:45-15:30 |
Debate: General anesthesia in older person patients |
|
Diabetes in older persons |
|
and Alzheimer's disease: Link proven? |
|
Capsule: |
Diabetes is prevalent in up to 20% of the older persons' population leading to increased risk of cardiovascular, neurological and infectious diseases. How tight does the glycemic control have to be during acute disease and during stable health conditions? |
|
Yes: P.K. Mandal, India
No: V. Fodale, Italy
|
|
Chairpersons: |
Y. Berner, Israel; D. Tessier, Canada |
15:30-15:45 |
Waiting in a hospital for nursing home admission: A one-way journey: J. Hewitt, Canada |
|
|
|
|
|
14:45-15:30 |
Debate: Diabetes control in older persons and very old persons |
15:45-16:00 |
The balance between new technologies, reliability and health care accuracy using dual energy X-ray absorptiometry: |
|
Pro, Glycemic control with Hba1c of 7% in older persons:
B. Itzhak, Israel |
|
J.P. Clarys, Belgium
|
|
Con, The risk of tight glycemic control in older persons is not worth the benfit:
D. Tessier, Canda |
|
|
|
|
|
|
|
15:30-15:40 |
Risk factors for mortality in a 19-year old prospective US study: Obesity reduces mortality risk for older adults:
P. Lantz, USA |
|
|
|
15:40-15:50 |
Diabetes, obesity and mortality in 3978 Chinese older adults: A 6-year follow-up study with DXA: J. Lee, China
|
|
|
|
15:50-16:00 |
A study to investigate barriers to diabetes self-care from both patients' and healthcare providers' perspectives in Hong Kong, China:
S. Pun, Hong Kong |
|
|
|
|
|
|
| 16:00-16:30 |
Coffee Break - Poster Session |
|
|
|
|
|
|
| 16:30-18 :30 |
Plenary Session |
|
Oral Presentations I |
|
Chairperson:
|
I. Turcu, Romania
|
| 16:30-16:40 |
Legitimizing deaths from "old age" - arguments for and against the formal recognition of this increasing reality:
J. Hewitt, Canada |
|
|
| 16:40-16:50 |
History of postponing human aging and prolonging life:
E. Taidre, Estonia |
|
|
| 16:50-17:00 |
Impact of medical morbidities on odds of achieving exceptional survival in an historical birth cohort:
P. Targonski, USA |
|
|
| 17:00-17:10 |
Profiling the elderly in oral anticoagulant therapy: Genetics, informatics and clinical practice:
G. Ogliari, Italy |
|
|
| 17:10-17:20 |
Pain management and the impact of pain on quality of life in nursing home residents:
E. Adler, Israel |
|
|
| 17:20-17:30 |
Handwriting performance measures of "real life" tasks among patients with Parkinson's disease and controls: Insights for rehabilitation strategies development:
S. Rosenblum, Israel |
|
|
| 17:30-17:40 |
Direct relationship of body mass index and waist circumference with body tissue distribution in elderly persons:
A. Scafoglieri, Belgium |
|
|
| 17:40-17:50 |
Research and practical implementation strategies in postponing aging:
U. Kristjuhan, Estonia |
|
|
| 17:50-18:00 |
Chronic disease self-management: Too old to learn? Too old to teach?
E. Hui, Hong Kong |
|
|
| 18:00-18:10 |
Secondary hyperparathyroidism and its relation with Sarcopenia and bone mass in elderly women:
L. Martini, Brazil |
|
|
| 18:10-18:20 |
Reminiscing: The impact on diverse elders and students who listen:
K. Carey, USA |
|
|
| 18:20-18:30 |
Factors influencing healthy lifestyles in older adults from minority cultures:
A. Schwingel, USA |
|
|
|
|
Parallel Session |
|
Parellel Session |
|
|
New concepts in dementia |
|
Treatment of overactive bladder |
|
Capsule: |
Cognitive disorders such as Alzheimer's disease are the most distressing conditions of aging. Some cognitive impairment can be detected early and be treated with cognitive exercise and by drugs. Should reatment be started as soon as early changes are detected? |
Capsule: |
Overactive bladder and urge incontinence prevalence both increase in old age. Antimuscarinic drugs are the first line therapy |
|
Chairpersons: |
A. Korczyn, Israel; J. Kulisevsky, Spain |
Chairperson: |
E. Topinkova, Czech Republic |
|
|
|
|
|
09:00-09:30 |
Is vascular cognitive impairment a useful concept?
A. Korczyn, Israel |
09:00-09:45 |
Debate: Evidence of antimuscarinics efficacy in old age? Is there a clinically significant risk of treatment? |
|
|
|
|
|
|
|
|
|
Efficacy of antimuscarinics in OAB symptoms:
E. Topinkova, Czech Republic |
|
09:30-10:15 |
Debate: The top 10 modifiable risk factors for dementia: Truth or fiction? |
|
Anticholinergic burden and risk of antimuscarinic drugs in older person patients and in the cognitively impaired:
A. Wagg, UK |
|
|
Truth: D. Gustafson, Sweden |
|
|
|
|
Fiction: J. Luchsinger, USA |
|
Parallel Session |
|
|
|
|
Clinical pharmacology in the elderly |
|
10:15-10:30 |
Discussion
|
Capsule: |
The elderly are the main consumers of drugs. With the physiological changes in aging, the risk of side-effects is increased - what is the
optimal amount of drugs that the older patient can benefit from with
the least harm involved? |
|
|
|
Chairperson: |
G. Gambassi, Italy |
|
|
|
|
|
|
|
|
09:45-10:30 |
Debate: The benefits and the burden of drugs in older person patients |
|
|
|
|
Controversies in geriatric polypharmacy: Does drug withdrawal prolong life?
D. Garfinkel, Israel |
|
|
|
|
Potential of beneficial drugs (polypill):
G. Onder, Italy |
|
|
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
|
|
|
|
|
Parallel Session |
|
Parallel Session |
|
|
Hormone replacement therapy in the female |
|
Growth hormone in older persons |
|
Capsule: |
Over the last 50 years significant experience has been gathered in Hormone Replacement therapy for women
of different ages. With great influence on the quality
of life as well as certain changes in the prevalence of diseases, are the benefits worth the risk? |
Capsule:
|
Growth Hormone deficiency leads to the same signs and symptoms as aging. Can we use it to modulate the aging process? |
|
Chairpersons: |
Z. Shoham, Israel; K. Biberoglu, Turkey |
Chairperson: |
V. Khavinson, Russia |
|
|
|
|
|
|
|
11:00-11:50 |
Debate: Growth hormone in older persons: Cancer risk, premature death or life |
|
11:00-11:45 |
Debate: Management of menopause |
|
extending & anti-cancer effects?
|
|
|
Should menopause be declared as a pathological state and therefore deserve treatment?
Z. Shoham, Israel |
|
Pro: T. Hertoghe, Belgium
Con: A. Chaturvedi, India/USA |
|
No treatment is needed during menopause in a asymptomatic woman: K. Biberoglu, Turkey |
11:50-12:15
|
Effects of hormone therapy on depresive symptoms in women with Alzheimer's disease:
A. Valen-Sendstad, Norway
|
|
|
|
|
Parallel Session |
|
11:45-12:00 |
Estrogen does not increase breast cancer risk in a way we need to worry about: HRT and breast cancer - Pros and Cons:
G. Kopernik, Israel |
Capsule:
|
Sleeping disorders
Sleeping disorders are very common in older persons. Drug side effects are very prevalent. How can we optimally manage these disorders which influence the quality of life of the patient as well as his environment? |
|
|
|
Chairpersons: |
A. Milicevic Kalasic, Serbia; I. Haimov, Israel |
|
12:00-12:15 |
Does testosterone treatment improve outcome in older age? Pros and Cons:
G. Corona, Italy |
12:15-12:25 |
Use of alternative medicine for sleeping disorders:
W. Winit-Watjana, UK |
|
|
|
|
|
|
12:15-12:30 |
Can testosterone play a role in the worldwide epidemic of obesity?
F. Saad, Germany
|
12:25-12:40 |
Use of drugs:
Y. Berner, Israel
|
|
12:30-12:40 |
Controversies in body mass index and human capacity in aging: O. Tomarevska, Ukraine |
12:40-12:50
|
Behavior of cancer in the aged implies a specific therapeutic approach: J. Leibovici, Israel |
|
|
|
|
|
|
12:40-12:50 |
Free androgen index and anthropometry, physical performance measures, health-related
quality of life, psychological incident, falls and |
12:50-13:00 |
Transcriptional biomarkers of age and their modulations by dietary interventions:
J. Barger, USA |
|
|
fractures in 1488 older men aged 65 years and over: A 4-year prospective study:
J. Woo, Hong Kong |
|
|
|
|
|
|
|
|
12:50-13:00 |
Panax ginseng enlivens testicular function in old rats:
S.K. Kim, South Korea |
|
|
|
|
|
|
|
|
13:00-14:00 |
Lunch Break |
|
|
|
|
|
|
|
|
|
Parellel Session |
|
Parellel Session |
|
|
Can we treat Sarcopenia in older persons? |
|
Cerebral vascular disease in older persons |
|
Capsule: |
Loss of muscle mass is common in older persons especially during health problems. With nutritional supplements and manipulation, can we prevent it or at least reduce its rate during active life and during
acute active disease? |
Capsule: |
Treatment with streptokinase becomes the "state of the art" treatment of thromboembolic cerebral events. It is an expensive treatment that needs masive infrastructure. It has to be performed in the first hours. Elderly vasculature has certain features that sometimes may increase the risks |
|
Moderator: |
C. Leeuwenburgh, USA |
Chairpersons: |
T. Grodzicki, Poland; A. Korczyn, Israel |
|
|
|
|
|
|
14:00-15:00 |
Debate: Can we treat Sarcopenia in older persons? |
14:00-14:45 |
Debate: Patients over 80 years old should be given the same secondary stroke prophylaxis as those under 80 |
|
|
Pro, Sarcopenia of older persons is a reversable and treatable condition and intervention may decrease frailty in older persons: T. Manini, USA |
|
Pro: D. Russell, Norway
Con: N. Bornstein, Israel |
|
|
Con, Sarcopenia of older persons is primarily an intrinsic process: J. Bauer, Germany |
|
|
|
|
|
|
Parallel Session |
|
15:00-15:30 |
Summary: C. Leeuwenburgh, USA
|
Capsule:
|
Treatment of atrial fibrillation in older persons
Atrial fibrillation increases with age and is responsible for many medical problems. Nevertheless, its treatment is sometimes futile and sometimes increases the risk of complications in older persons. It raises the question of whether to use anti-coagulation in order to decrease the complications from atrial fibrillation and the influence of medical treatment on the health of the patient |
|
|
|
Chairpersons: |
Y. Berner, Israel |
|
|
|
|
|
|
|
|
14:45-15:30 |
Debate: Atrial fibrillation in older persons |
|
|
|
|
Rate or rhythm control?
Y. Berner, Israel |
|
|
|
|
Anticoagulation: The benefits and the risks?
A.J. Cruz Jentoft, Spain |
|
|
|
|
|
|
15:30-16:00 |
Coffee Break |
|
|
|
|
|
|
|
|
|
Parallel Session |
|
Parallel Session |
|
|
Osteoarthristis in older persons: Can we prevent it or just teat the pain? |
|
Special clinical problems in the care of older persons |
|
Capsule: |
Changes in the structure and metabolism of the bone are very common in older person patients in the spine, and significant pain. The use of pharmacological and hormonal treatment has become the standard treatment for osteoporosis. From what treatment do the older persons really benefit? |
Capsule: |
Atrial fibrillatio increases with age and is responsible for many medical problems. Nevertheless, its treatment is sometimes futile and sometimes increases the risk of complications in older persons. It raises the question of whether to use anti-coagulation in order to decrease the complications from atrial fibrillation and the influence of medical treatment on the health of the patient |
|
Chairperson: |
M. Hochberg, USA |
Chairperson: |
E. Topinkova, Czech Repbulic; A.J. Cruz Jentoft, Spain |
|
|
|
|
|
|
16:00-16:20 |
Do treatments for symptomaic OA after the long-term prognosis of the patient?
J. Monfort, Spain |
16:00-16:20 |
What are the ethical implications for a patient whose stem cells do not recover sufficiently for use in the proposed therapy? Does this imply an underlying defect previously |
|
|
|
|
undected? Does this have lifespan inpilcations?
N.R. Forsyth, UK
|
|
16:20-16:40 |
Can OA be prevented?
G. Herrero-Beaumont, Spain |
|
Does palliative care provision improve healthcare service efficienty and quality of life in older patients with chronic obstructive pulmonary disease?
|
|
|
|
|
|
|
16:40-17:00 |
Is OA associated with reduced longevity?
M. Hochberg, USA |
16:40-17:05 |
Social care research ethics, mental capacity in older people:
D. Stanley, UK |
|
|
|
|
|
|
17:00-17:20 |
Strontium Ralenate reduces vertebral fractures in frail osteoporotic women: Can it be prevented?
Y. Rolland, France |
17:05-17:30 |
Prevention of a public health problem: Osteoporosis:
Y. Gokce Kustal, Turkey |
|
|
|
|
|
|
17:20-17:40 |
Pain treatment: When to stop, for how long and how to evaluate the patients before starting treatment:
N. Van Den Noortgate, Belgium |
17:30-17:40 |
Oxidative stress and age-related alterations of paraoxanse 1 in the process of atherosclerosis:A. Khalil, Canada |
|
|
|
|
|
|
17:40-18:00 |
Beleive in just world among eldery as a coping mechanism: Measured through the geriatric depression scale:
J. Doumit, Lebanon |
17:40-17:50 |
Tobacco industry impact on geriatric science and health care:
J. Cataldo, USA
|
|
|
|
|
Testosterone is a determinant of longevity, health and aging:
F. Saad, Germany |
| 09:00-10:30 |
Plenary Session |
|
Oral presentations II |
|
Chairperson:
|
Y. Rolland, France
|
| 09:00-09:10 |
IGF-1 system and healthy aging: Modulation of functional and cognitive status in centenarians and their offspring:
G. Ogliari, Italy |
|
|
| 09:10-09:20 |
A history of diabetes increases the risk of dementia in people with a borderline mini-mental state examination score: The health in men study:
H. Alfonso, Australia |
|
|
| 09:20-09:30 |
Conceptual challenges in exploring the role of ICT in successful aging:
M. Gilhooly, UK |
|
|
| 09:30-09:40 |
Subthreshold depression and slowing across multiple functional domains:
S. Albert, USA |
|
|
| 09:40-09:50 |
Pr evalence of depressive symptoms among beneficiaries of the Red Cross programme for the elderly:
A. Milicevic Kalasic, Serbia |
|
|
| 09:50-10:00 |
Living in retirement communities in the USA and Poland:
A. Zurek, Poland |
|
|
| 10:00-10:10 |
Differences between centenarians and nonagenarians admitted to hospital:
O.H. Torres, Spain |
|
|
| 10:10-10:20 |
The Functional Characteristics of “Aged” Chromosomes:
T. Lezhava, Georgia |
| |
|
| 10:20-10:30 |
Depression in the elderly residing in Northwest Tehran-Iran:
F. Mousavi, Iran |
|
|
| 10:30-11:00 |
Coffee Break |
|
|
| 11:00-12:30 |
Plenary Session |
|
Role of caloric restriction in human aging |
| Capsule: |
Since the 1930's caloric restriction remains the main method for longevity in different species. Caloric restriction in humans may increase health risks, especially malnutrition. Can we recommend caloric restriction in a younger age in order to reach longevity in better health? Should certain people gain weight and remain obese
in order to survive the longest? |
| Chairpersons: |
Y. Berner, Israel; B. Vellas, France |
|
|
| 11:00-11:15 |
Molecular mechanisms of lifespan extension by calorie restriction:
C. Leeuwenburgh, USA |
|
|
| 11:15-11:30 |
Are Sirtuins true regulators of lifespan in higher organisms and do they influence calorie restriction?
R. De Cabo, USA |
|
|
| 11:30-11:45 |
Nutritional modulation of aging and age-associated diseases by caloric restriciton in humans:
Y. Berner, Israel |
|
|
| 11:45-12:00 |
Nutritional mitigation of oxidative and inflammatory stress signal and brain aging:
J. Joseph, USA |
|
|
| 12:00-12:15 |
Variable cognitive benefits in HAART-treated patients: Is aging and low cholsterol linked?
M. Miguez, USA |
|
|
| 12:15-12:30 |
Discussion |
|
|
|
12:30-13:30 |
Closing |
|
|
|
|
WebStudio.co.il